Phase 2 trial of dovitinib in Bacillus Calmette-Guerin (BCG) refractory urothelial carcinoma (UC) with tumor FGFR3 mutations or over-expression: Hoosier Cancer Research Network GU12-157.
Year: 2016
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Noah M. Hahn, Trinity J. Bivalacqua, Ashley Ross, George J. Netto, Jong Chul Park, Timothy A. Masterson, Michael O. Koch, Richard Bihrle, Richard Foster, Thomas A. Gardner, Liang Cheng, David R Jones, Kyle McElyea, George Sandusky, Ziyue Liu, Scott A Turner, Gregory J. Tsongalis, Elizabeth R. Plimack, Richard E. Greenberg, Daniel M. Geynisman
Institutions: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, Indiana University School of Medicine, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Dartmouth College, Dartmouth–Hitchcock Medical Center, Fox Chase Cancer Center
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2502912197